A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole (5 mg QD, 20 mg QD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis.

Trial Profile

A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole (5 mg QD, 20 mg QD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Ilaprazole (Primary) ; Lansoprazole (Primary)
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 01 Jan 2008 Status changed from in progress to completed.
    • 26 Jul 2007 Status changed from recruiting to in progress.
    • 03 Jul 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top